A5074516113- Acute Myeloid Leukemia Research
- Histone Deacetylase Inhibitors Research
- Pharmacogenetics and Drug Metabolism
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Immune cells in cancer
- CAR-T cell therapy research
- Lung Cancer Research Studies
Chinese University of Hong Kong
2022-2024
Abstract Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by impaired terminal differentiation. Despite intensive treatment regimes, the clinical outcomes remain suboptimal. Here, we report a new mechanism involving tetraspanin protein CD9 in orchestrating differentiation arrest and immune escape pediatric AML. The expression of on blasts AML patients (12.5%, n=115) was significantly lower than those ALL (93.6%, n=343, P<0.0001) or hematopoietic stem...
Abstract Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging due to inherent differences underlying genetics. Here we established pharmacologic profile pediatric AML by screening myeloblast sensitivity approved and investigational agents, revealing candidates immediate clinical relevance. Drug responses ex vivo correlated patient characteristics, exhibited age-specific alterations, concorded...
Resistance to glucocorticoids (GC), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting mechanisms shaping GC resistance could lead new treatment modalities. Here, we showed that CD9- BCP-ALL cells were preferentially resistant prednisone and dexamethasone over other standard cytotoxic agents. Concordantly, identified significantly more poor responders prephase among...
<div>Abstract<p>Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging due to inherent differences underlying genetics. Here we established pharmacologic profile pediatric AML by screening myeloblast sensitivity approved and investigational agents, revealing candidates immediate clinical relevance. Drug responses <i>ex vivo</i> correlated patient characteristics, exhibited...
<div>Abstract<p>Despite the expanding portfolio of targeted therapies for adults with acute myeloid leukemia (AML), direct implementation in children is challenging due to inherent differences underlying genetics. Here we established pharmacologic profile pediatric AML by screening myeloblast sensitivity approved and investigational agents, revealing candidates immediate clinical relevance. Drug responses <i>ex vivo</i> correlated patient characteristics, exhibited...
Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Figure from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine
Supplementary Data from Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision Medicine